India Investment, Stocks, Credit Card and Retail Forum

Investments in Indian Equity and Research => Equity Investments, Fundamental Research and Sectors Review => Sensex and Nifty Company Analysis => Topic started by: komal on June 28, 2012, 11:19:05 AM

Title: BUY Lupin Labs Review - Morgan
Post by: komal on June 28, 2012, 11:19:05 AM
Morgan Stanley has reiterated OVERWEIGHT rating on Lupin and has revised EPS expectations upwards for FY 13 and FY 14. In a report it has said,

Quote
...on its earnings momentum (2-year EPS CAGR: 29% vs. industry’s 18%), driven by all-around performance (US, India, Japan, South Africa) and strong US pipeline. We raise our PT to Rs652, and examine two key investor debates: Suprax and US OC market outlook

FY13 EPS 26.89
FY14 EPS  34.30

Target Rs 652, potential upside of 24% from current levels.